Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6799682 | 0.94 | CRHR1 (0.51) | CRHR1POLBTSHRMAPK1CYP1A2 | |
| SCHEMBL5844580 | 0.90 | CRHR1 (0.72) | CRHR1 | |
| SCHEMBL6793471 | 0.88 | CRHR1 (0.59) | CRHR1CYP1A2CYP2C19SMN1; SMN2LMNA | |
| SCHEMBL6804572 | 0.86 | CRHR1 (0.57) | CRHR1POLBTSHRMAPK1CYP1A2 | |
| SCHEMBL5845187 | 0.85 | CRHR1 (0.79) | CRHR1 | |
| SCHEMBL6799763 | 0.83 | CRHR1 (0.51) | CRHR1POLBTSHRMAPK1 | |
| SCHEMBL6798181 | 0.82 | CRHR1 (0.52) | CRHR1CYP1A2CYP2C19SMN1; SMN2CYP3A4 | |
| SCHEMBL6796769 | 0.81 | CRHR1 (0.59) | CRHR1 | |
| SCHEMBL6798703 | 0.79 | CRHR1 (0.57) | CRHR1 | |
| SCHEMBL6798443 | 0.79 | CRHR1 (0.57) | CRHR1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6833378-B2 | Pyridines, pyrimidines, purinones, pyrrolopyrimidinones and pyrrolopyridinones; useful in the treatment disorders including CNS and stress-related disorders. | PFIZER INC | 2004-12-21 | — | — | US | disclosed |
| EP-1263732-A1 | CORTICOTROPIN RELEASING FACTOR ANTAGONISTS | Pfizer Products Inc. (US) | 2002-12-11 | — | — | EP | disclosed |
| US-20020016328-A1 | Corticotropin releasing factor antagonists | PFIZER INC. | 2002-02-07 | — | — | US | disclosed |
| WO-2001053263-A1 | CORTICOTROPIN RELEASING FACTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2001-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020016328-A1 | Corticotropin releasing factor antagonists | CRH, CRHR2, CRHR1 | CRHR1 3/4885POLB 4331/4885TSHR 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.